Is giritinib (segatan) a targeted drug or a chemotherapy drug?

Gilteritinib is a targeted therapy drug, not a chemotherapy drug. It belongs to a class of drugs called tyrosine kinase inhibitors, which work by inhibiting abnormally active tyrosine kinases in cells to help control the proliferation and spread of leukemia cells.

Targeted therapy drugs are different from traditional chemotherapy drugs in their mechanisms of action and treatment methods. Chemotherapy drugs usually kill rapidly proliferating cancer cells by interfering with cells' DNA synthesis or interfering with cell division, but they can also affect normal cells, causing a wide range of side effects. Targeted therapy drugs have a more specific effect and can accurately interfere with specific molecular pathways or targets in cancer cells, thereby inhibiting the proliferation and survival of cancer cells. They have relatively little impact on normal cells, so they usually have lower side effects.

In the treatment of leukemia, gilitinib mainly targetsFLT3kinase. FLT3kinase plays an important role in regulating cell proliferation and survival in normal cells, but in leukemia cells, especially those cells carrying FLT3 mutations, its activity is abnormally enhanced. The function of giritinib is to selectively inhibit the activity of FLT3 kinase, thereby preventing the proliferation and survival of leukemia cells, helping to control the disease and prolong the survival time of patients.

Overall, giritinib, as a targeted therapy, has shown significant efficacy in treating leukemia and generally has fewer side effects. Compared with traditional chemotherapy drugs, targeted therapy drugs provide more precise and effective treatment options, bringing better treatment prospects to leukemia patients.